Comparative Pharmacology
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMECLOCYCLINE HYDROCHLORIDE versus TETRAMED.
DEMECLOCYCLINE HYDROCHLORIDE vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, inhibiting protein synthesis by preventing aminoacyl-tRNA from attaching to the mRNA-ribosome complex.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
150 mg orally every 6 hours or 300 mg orally every 12 hours. Maximum daily dose: 1200 mg.
100 mg orally every 12 hours
None Documented
None Documented
10-17 hours; prolonged in renal impairment (up to 40–50 hours)
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Renal: 40-50% unchanged; fecal/biliary: 10-15%
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic